What is it about?
Our study shows that people taking ACE inhibitors had a lower long‑term cancer risk compared to those taking ARBs. After following more than 423,000 adults for up to 23 years, cancer was diagnosed in 56% of ACEI users versus 61% of ARB users a meaningful difference. While results varied by cancer type, the overall pattern suggests these two common treatments may not carry the same cancer risks
Featured Image
Photo by danilo.alvesd on Unsplash
Why is it important?
ACE inhibitors and ARBs are two of the most common medications for blood pressure. Millions of people take them for many years. If one of these treatments is linked to a higher long‑term cancer risk, even slightly, that matters for everyone patients, doctors, and public health. Understanding these differences can help people make safer treatment choices and guide future research to protect long‑term health.
Perspectives
From my perspective, this study is important because ACE inhibitors and ARBs are medications that millions of people take every day, often for many years. If one of these treatments carries even a slightly different long‑term cancer risk, people deserve to know that. As someone who cares about patient safety and clear medical decision‑making, understanding these differences helps doctors choose the safest option and gives patients more confidence in their treatment. For me, this research is about protecting long term health and making sure the medications we rely on truly support our well‑being.
Belle Tamir Brahms
1. Department of Family Medicine, Clalit Health Services, Sharon-Shomron, District
Read the Original
This page is a summary of: A comparative analysis of ACE Inhibitors and ARBs as cancer risk factors, PLOS One, July 2026, PLOS,
DOI: 10.1371/journal.pone.0354248.
You can read the full text:
Contributors
The following have contributed to this page
